Nemaura Medical Inc. Successfully Completes Development of Second-Generation sugarBEAT ® Non-Invasive Continuous Glucose Monitoring Skin-Patch

IN.PACT AV Drug-Coated Balloon Is First and Only to Show Superior and Sustained Results Through Two Years Compared to PTA in Treating Arteriovenous Fistulae Lesions

The data, which were presented virtually as a podium first at the 2021 Charing Cross Symposium, demonstrated that the IN.PACT™ AV drug-coated balloon (DCB) is the first and only DCB to show sustained and superior effectiveness through two years compared to standard percutaneous transluminal angioplasty (PTA) in end-stage renal disease (ESRD) patients with de novo or non-stented restenotic native arteriovenous fistulae (AVF) in the upper extremity.

Martell Diagnostic Laboratories Announces HERTEST: Groundbreaking Way to Detect Effectiveness of Breast Cancer RX Globally

HERTEST is a blood test that looks for a protein called human epidermal growth factor receptor (HER2), which is shed into the blood stream of patients with growing breast cancer tumors.

ESPRIT CAM Improves Productivity for Long Part Machining by Automating Multi-spindle Program Creation

ESPRIT CAM: New computer-aided-manufacturing (CAM) technology has been introduced by ESPRIT CAM, part of Hexagon’s Manufacturing Intelligence division that provides manufacturers with the control and flexibility needed to use multi-spindle and multi-channel computer-numerical-control (CNC) machinery for the machining of long parts.

April 25, 2017

Nemaura Medical Inc. (OTCBB: NMRD), a medical device company has today announced the successful completion of the development and testing of its second-generation sugarBEAT® wireless skin-patch as a non-invasive, needle-free Continuous Glucose Monitoring (CGM) system for use by diabetics.

Nemaura Medical notes their first-generation sugarBEAT® received CE approval in Q1 2016, as a wired wrist-watch based non-invasive, needle-free CGM system.

Clinical trials on the second-generation sugarBEAT® wireless skin-patch are due to get underway soon with a view to submitting CE approval mid-year. The company expects to launch sugarBEAT® in Europe later this year through its European Licensee.

The daily-disposable format of the sugarBEAT® skin-patch is expected to provide a much more flexible way for diabetics to better manage their glucose levels. Furthermore, sugarBEAT’s® cost-effective design, consisting of a reusable Bluetooth-enabled body-worn transmitter containing a low-cost disposable adhesive skin-patch will make CGM more affordable, especially for non-insulin-injecting diabetics.

Nemaura Medical CEO Dr Faz Chowdhury said: “Adopting a wireless skin-patch format has allowed us to seamlessly integrate our needle-free technology with a diabetic’s own smart device. We have also further refined and enhanced our sensor performance, and are confident that this year’s clinical trials will confirm the efficacy of sugarBEAT® in helping to improve personal healthcare management for anyone living with diabetes. ”

Alongside the sugarBEAT® wireless skin-patch, Nemaura has also successfully developed and tested the associated sugarBEAT® mobile phone application. This Medical-grade App connects by Bluetooth to the skin-patch and displays glucose readings on a continuous basis as well as providing summary Ambulatory Glucose Profile (AGP) trends. The App also allows for additional manual lifestyle inputs helping diabetics to better understand and manage their condition.



Related Articles